SOLO-2 Results: Maintenance Therapy with Lynparza Extends Survival in Relapsed Ovarian Cancer

SOLO-2 Results: Maintenance Therapy with Lynparza Extends Survival in Relapsed Ovarian Cancer
Maintenance therapy with AstraZeneca’s Lynparza (olaparib) extended survival by more than one year in women with BRCA-mutated relapsed ovarian cancer, whose tumors responded to platinum-based chemotherapy, final results from the SOLO-2 Phase 3 clinical trial show. Trial findings, “Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation," will be presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held online May 29–31. A video presentation is available now. Lynparza is a so-called PARP inhibitor as it works by blocking the PARP enzyme, which plays a role in repairing DNA errors in cells. The oral medication is particularly effective in cancers with mutations in other DNA-repairing genes, such as BRCA1 and BRCA2, because they rely mainly on the PARP enzymes to repair DNA damage and avoid tumor cell death. SOLO-2 (NCT01874353) evaluated Lynparza as a maintenance therapy for women with relapsed BRCA-related ovarian cancer who had responded to their most recent platinum-based chemotherapy after having received at least one more line of chemotherapy. The trial was funded by AstraZeneca and MSD, known as Merck in the U.S. and Canada. A total of 195 women were treated with 300 mg tablets of Lynparza given twice daily, and 99 received a placebo. Treatment was given until disease progression or the occurrence of serious toxicity. Results showed that 42.1% of women on Lynparza were alive at five years of follow up, compared to 33.2% of women on a placebo. Median overall survival was 51.7 months with Lynparza and 38.8 months with a placebo, meaning survival extension
Subscribe or to access all post and page content.